The growth of Viagra and its knockoff effect on the pharmaceutical landscape presents a intricate question for shareholders. While the early sales figures were astounding, the exclusivity has expired, leading to a wave of off-brand alternatives that are eroding earnings. Furthermore, the industry is facing difficulties related to demographic trends